Riviciclib hydrochloride (P276-00) is a novel inhibitor of CDK1, CDK4, and CDK9, with IC50 values of 79 nM, 63 nM, and 20 nM, respectively; it is under Phase 2/3 clinical investigation. It exhibits potent antiproliferative effects against various human cancer cell lines, including HCT-116, U2OS, H-460, HL-60, HT-29, SiHa, MCF-7, Colo-205, SW-480, PC-3, Caco-2, and T-24, with IC50 values ranging from 300 to 800 nmol/L, and shows higher selectivity for cancer cells over normal fibroblasts. It downregulates cyclin D1 and Cdk4 in an ATP-competitive manner and reduces Cdk4-specific phosphorylation of pRb at Ser780. Additionally, it induces apoptosis by activating caspase-3 and promoting DNA laddering. In vivo, it significantly inhibits tumor growth in mouse models of colon cancer (CA-51) and Lewis lung carcinoma, as well as in human HCT-116 colon carcinoma and H-460 non-small cell lung cancer xenografts.